Alpha Tau Medical Ltd. (DRTSW)

Alpha Tau Medical Ltd. is a clinical-stage oncology company developing an innovative form of radiation therapy called Alpha DaRT — Diffusing Alpha-emitters Radiation Therapy. The company, based in Israel and publicly traded in the United States, is trying to prove that alpha particles, a form of radiation that has been studied for decades but never widely deployed in clinics, can treat solid cancers better than the radiation methods doctors use today. The fight is not against one competitor but against the established standard of care — external-beam radiation and brachytherapy, the proven and profitable treatments that nearly every cancer center already uses.

Alpha Tau was founded around 2016 to commercialize alpha-particle therapy technology originally developed at Tel Aviv University by Prof. Itzhak Kelson and Prof. Yona Keisari. The founding scientists recognized that alpha particles are ideal in some ways: they deliver extremely high energy over very short distances, so they can damage tumor cells intensely while sparing tissue just beyond the tumor boundary. The problem was practical: alpha emitters are short-lived and dangerous to handle, and no one had figured out how to deploy them safely inside a patient’s body as a therapy.

Alpha Tau’s approach was to impregnate small radioactive seeds with radium-224, a short-lived alpha emitter, and inject them directly into tumors under image guidance. The seeds stay in the tumor, continuously releasing alpha particles into the surrounding tissue for days, and then the radium decays to a stable form and poses no ongoing risk. In theory, this method delivers a much higher dose of radiation to the tumor than external beams can achieve, while limiting the damage to healthy tissue nearby.

The evidence so far, from early human trials, has been promising. In trials for skin cancers and head-and-neck tumors, Alpha DaRT has shown high response rates — some reaching 100% local disease control — with manageable side effects. More recently, the company has begun testing Alpha DaRT in harder targets: pancreatic cancer, glioblastoma, and other aggressive internal tumors where standard radiation has historically performed poorly. As of early 2026, Alpha Tau has five concurrent clinical trials running in the United States, with data readouts expected through the year.

Why Alpha Tau is not inevitable

The fundamental question about Alpha Tau is not whether alpha radiation works — the physics is sound and the early data is genuinely encouraging — but whether it can displace radiation therapy that is already practiced in thousands of hospitals worldwide. External-beam radiation is mature, reliable, inexpensive to deliver (once a hospital has bought the machine), and reimbursed by insurance. Every cancer center already has a radiation oncologist and the supporting equipment. Adding Alpha Tau would require doctors to learn a new technique, patients to accept an interventional procedure, and hospitals to buy new equipment or partner with specialized centers.

That adoption barrier is steep. A cancer center considering Alpha DaRT must believe, on the basis of trial data, that it will improve patient outcomes enough to justify the disruption and cost. That belief grows stronger as data accumulates, but data takes years to gather. Trials are slow, patient recruitment is hard, and reading the results — especially in cancer, where survival may take years to assess — is a years-long process in itself.

Alpha Tau also competes indirectly against innovation in other modalities. Immunotherapy, newer chemotherapy combinations, and genetic therapies are all advancing at the same time. If another treatment proves dramatically better for pancreatic cancer than radiation ever could, Alpha DaRT’s positioning in that disease shrinks. So Alpha Tau is not just racing to prove its technology works; it is racing against time and against the entire oncology innovation ecosystem.

Scaling manufacturing is another challenge. The seeds must be assembled, quality-controlled, loaded with radium-224, and delivered to hospitals in sealed containers, all on a tight timeline because the radium decays. Building a supply chain that is safe, reliable, and cost-effective at scale is non-trivial. Early on, Alpha Tau could afford to manufacture in small batches; eventually, if the product reaches the market, manufacturing becomes a serious business operation.

The path to commercialization

If Alpha Tau’s trials succeed — if the data is strong enough that physicians believe Alpha DaRT is better than the alternative, and regulators agree — then the company needs to get the product approved by the FDA (or equivalent regulators worldwide). That approval would likely be on an indication-by-indication basis: an approval for recurrent glioblastoma, separate approval for skin cancer, separate approval for pancreatic cancer, and so on. Each indication is a separate regulatory battle.

After approval comes adoption. Alpha Tau would need to train physicians, partner with hospitals, set up manufacturing, and convince insurers to reimburse the procedure. All of that takes time and money. The company’s burn rate is high — it is pre-revenue and funding clinical trials — which means it will need capital, either from investors or eventually from partnerships with larger pharmaceutical or medical-device companies.

Researching Alpha Tau

For investors evaluating Alpha Tau, the 10-K filing (SEC CIK 0001871321) is essential. It lays out the clinical trial status, the timeline for data readouts, the cash runway, and the regulatory path. The quarterly updates and press releases from the company are also valuable; they track which trials have enrolled their first patients, which have reported interim data, and what the safety profile has been. A reader should understand the clinical trial landscape in each indication the company is pursuing — how many patients are enrolled, what the trial’s statistical design is, and what would constitute a meaningful positive result.

The risk profile is binary: if the trials fail to show compelling benefit, the stock likely becomes worthless. If they succeed and the product reaches the market, the upside could be substantial, because the addressable market in cancer is enormous and the margins on a novel, differentiated therapy are typically high. That risk-reward asymmetry is why Alpha Tau attracts venture and growth investors, and why it is a volatile, early-stage biotech story.